Neuroendocrine Tumors

• 

  Subject Areas on Research

  • 68Ga-DOTATATE: Significance of Uptake in the Tail of the Pancreas in Patients Without Lesions. 
  • A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. 
  • A case report on metastatic ileal neuroendocrine neoplasm to the breast masquerading as primary breast cancer: A diagnostic challenge and management dilemma. 
  • A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. 
  • A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. 
  • A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. 
  • Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. 
  • Cadherin 17 is frequently expressed by 'sclerosing variant' pancreatic neuroendocrine tumour. 
  • Calcitonin driven v-Ha-ras induces multilineage pulmonary epithelial hyperplasias and neoplasms. 
  • Choroidal metastatasis from a neuroendocrine tumor masquerading as choroidal melanoma. 
  • Competing Mortality in Patients With Neuroendocrine Tumors. 
  • DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. 
  • Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. 
  • Early onset pancreatic malignancies: Clinical characteristics and survival associations. 
  • Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. 
  • Embryonic lethal abnormal visual RNA-binding proteins involved in growth, differentiation, and posttranscriptional gene expression. 
  • Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors. 
  • Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. 
  • Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. 
  • Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract. 
  • Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor. 
  • Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. 
  • In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous. 
  • Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors. 
  • Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. 
  • Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis. 
  • Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. 
  • Lipid-rich variant of a pancreatic endocrine neoplasm in an endoscopic ultrasound-guided fine needle aspiration biopsy. 
  • Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. 
  • Liver resection for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin: A multicentric study. 
  • Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. 
  • Management of advanced neuroendocrine tumors with hepatic metastasis. 
  • Mesenteric Tumor Deposits in Midgut Small Intestinal Neuroendocrine Tumors Are a Stronger Indicator Than Lymph Node Metastasis for Liver Metastasis and Poor Prognosis. 
  • Mesenteric tumour deposits arising from small-intestine neuroendocrine tumours are frequently associated with fibrosis and IgG4-expressing plasma cells. 
  • Molecular Imaging and Therapy for Neuroendocrine Tumors. 
  • Morphologic Spectrum of Neuroendocrine Tumors of the Prostate: An Updated Review. 
  • N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. 
  • NCCN practice guidelines for occult primary tumors. National Comprehensive Cancer Network. 
  • Neuroendocrine Neoplasms of the Appendix: A Review of the Literature. 
  • Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. 
  • Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy. 
  • Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy. 
  • Number, not size, of mesenteric tumor deposits affects prognosis of small intestinal well-differentiated neuroendocrine tumors. 
  • O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. 
  • Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours. 
  • Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study. 
  • Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database. 
  • Overexpression of SOX11 and TFE3 in Solid-Pseudopapillary Neoplasms of the Pancreas. 
  • Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies. 
  • Pancreatic FNA in 1000 cases: a comparison of imaging modalities. 
  • Pancreatic Neuroendocrine Tumors. 
  • Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT. 
  • Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. 
  • Pancreatic neuroendocrine tumors: pathologic and molecular characteristics. 
  • Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. 
  • Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. 
  • Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. 
  • Platinum sensitivity in metastatic prostate cancer: does histology matter? 
  • Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG. 
  • Proceed with caution: liver transplantation for metastatic neuroendocrine tumors. 
  • Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy. 
  • Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver. 
  • SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. 
  • Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. 
  • Serotonin expression in pancreatic neuroendocrine tumors correlates with a trabecular histologic pattern and large duct involvement. 
  • Should Ki67 immunohistochemistry be performed on all lesions in multifocal small intestinal neuroendocrine tumours? 
  • Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors? 
  • Small serotonin-producing neuroendocrine tumor of the pancreas associated with pancreatic duct obstruction. 
  • Synchronous resection of primary and liver metastases for neuroendocrine tumors. 
  • Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. 
  • The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. 
  • The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. 
  • Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. 
  • Two Extraordinary Sellar Neuronal Tumors: Literature Review and Comparison of Clinicopathologic Features. 
  • Update on Surgical Management of Small Bowel Neuroendocrine Tumors. 
  • Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 
  • Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. 
  • Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. 
• 

  Keywords of People

  • Yoo, Sua, Associate Professor of Radiation Oncology, Radiation Oncology